Clinical Significance of Bilateral Proptosis Multiple Myeloma

Encountering bilateral proptosis multiple myeloma in routine clinical practice represents an exceedingly rare and complex diagnostic challenge. Multiple myeloma typically manifests through bone pain, anemia, renal dysfunction, and hypercalcemia. However, extramedullary disease can occasionally develop when clonal plasma cells infiltrate tissues outside the bone marrow. Orbital plasmacytoma accounts for less than one percent of all orbital tumors. Furthermore, clinicians usually discover orbital involvement as a late secondary complication in patients with established disease. Presenting with bilateral orbital lesions as the initial sign of an undiagnosed hematologic malignancy remains extraordinary. Consequently, ophthalmologists and internists often suspect thyroid eye disease, orbital inflammatory pseudotumor, or vascular lesions before considering a plasma cell dyscrasia. A recent case report described a 40-year-old female presenting with rapid, severe exophthalmos that unmasked an underlying aggressive malignancy. Recognizing this atypical manifestation is critical because extramedullary dissemination indicates high-risk disease biology. Therefore, prompt clinical identification and urgent multi-specialty intervention remain essential to preserve residual vision and stabilize systemic health.

Clinical Presentation and Ocular Surface Complications

Extramedullary orbital involvement frequently presents with rapid progression, contrasting sharply with the indolent course of benign orbital diseases. In this recent case, the patient developed marked bilateral proptosis over a very short duration. Visual acuity declined dramatically because severe retrobulbar mass effects compromised the anterior visual pathways. In addition, the massive forward displacement of both globes triggered severe lagophthalmos. The resulting exposure caused advanced ocular surface compromise, extensive conjunctival chemosis, and deep corneal ulcerations. In severe presentations, patients can also develop scleromalacia and complete ophthalmoplegia. Mechanical compression of extraocular muscles and nerves severely impairs ocular motility. Therefore, ophthalmologists must conduct aggressive supportive care alongside systemic diagnostics. Clinicians must apply frequent topical lubricants, protective taping, and temporary tarsorrhaphy when necessary to avert corneal perforation. Because vision loss can become irreversible within days, clinicians must never delay diagnostic workup while treating superficial corneal injuries. Consequently, rapid identification of the underlying neoplastic process dictates both ocular and systemic survival.

Diagnostic Imaging and Histopathological Confirmation

Comprehensive radiological evaluation forms the cornerstone of evaluation when assessing severe exophthalmos. Magnetic resonance imaging of the brain and orbits typically delineates solid, expansile soft tissue masses. In the reported presentation, cranio-orbital imaging demonstrated bilateral extraconal masses exerting substantial pressure on the ocular globes. Notably, the expansile masses deformed the posterior aspect of the globes into a strawberry configuration without direct intraocular invasion. Computed tomography also revealed extensive adjacent osseous destruction involving the lateral orbital walls and skull base. Bone scintigraphy and skeletal surveys often demonstrate widespread lytic lesions across the calvarium. In addition to structural neuroimaging, clinicians must pursue tissue biopsy to achieve an unequivocal diagnosis. In this patient, histopathologic examination of a biopsied conjunctival lesion confirmed extramedullary plasmacytoma. Immunohistochemistry typically shows marked light chain restriction. Concurrently, serum immunoelectrophoresis identified monoclonal IgA kappa paraprotein, while bone marrow aspiration revealed 48 percent dystrophic plasma cells. Thus, combining tissue histology with serum protein electrophoresis rapidly confirms the diagnosis.

Pathophysiology of Orbital Plasmacytoma and Extramedullary Disease

The pathophysiological development of extramedullary plasmacytoma involves complex biological alterations in clonal plasma cells. Generally, multiple myeloma plasma cells depend heavily on the bone marrow microenvironment for survival and proliferation. However, aggressive sub-clones often downregulate crucial adhesion molecules such as CD56 and CXCR4. Consequently, these malignant cells detach from the marrow stroma and enter the peripheral circulation. Hematogenous seeding facilitates colonization of diverse vascular beds, including the superior-temporal quadrant of the orbit. Furthermore, specific immunoglobulin isotypes correlate with aggressive clinical behavior. While IgG myeloma remains the most prevalent variant overall, clinicians frequently encounter IgA isotype dominance in extramedullary disease. IgA myeloma carries an inherent propensity for atypical tissue infiltration, high tumor burden, and elevated therapy resistance. Additionally, genetic abnormalities such as TP53 deletions or 1q21 amplifications often drive this invasive behavior. Therefore, orbital involvement does not merely represent a localized structural problem. Instead, it reflects an underlying systemic expansion of dedifferentiated plasma cells possessing marked biological aggressiveness.

Therapeutic Strategies and Intensive Multidisciplinary Management

Managing extramedullary multiple myeloma requires immediate collaboration between hematologists, oncologists, radiation specialists, and ophthalmologists. Systemic therapy must commence urgently to halt rapid end-organ destruction. Modern induction regimens incorporate proteasome inhibitors like bortezomib, immunomodulatory agents, and high-dose dexamethasone. Corticosteroids provide vital immediate anti-myeloma activity while reducing acute orbital inflammation and optic nerve edema. Furthermore, clinicians often incorporate monoclonal antibodies targeting CD38, such as daratumumab, to enhance systemic cytoreduction. When progressive masses threaten irreversible optic neuropathy, emergency orbital external beam radiotherapy provides rapid local tumor debulking. In the reported case, the clinical team initiated high-dose corticosteroids and immunochemotherapy, producing notable initial local regression of orbital infiltration. However, systemic complications in aggressive myeloma can escalate swiftly. Clinicians must also provide vigorous supportive care, including hypercalcemia correction, infection prophylaxis, and renal protection. Although targeted multi-agent regimens induce rapid initial cytoreduction, sustaining systemic remission in extramedullary presentations remains a formidable therapeutic challenge.

Prognostic Implications and Vigilance for Clinicians

The emergence of extramedullary disease at initial presentation consistently heralds an adverse clinical prognosis. Historical clinical data demonstrate that patients with orbital plasmacytoma experience significantly shorter progression-free and overall survival than patients with purely medullary myeloma. In the featured case, the patient unfortunately succumbed shortly after achieving early orbital response. This tragic outcome underscores how massive systemic tumor burdens and treatment-related complications can overcome early therapeutic gains. Furthermore, presenting at a younger age does not shield individuals from fatal complications when aggressive phenotypes emerge. Therefore, internists and primary care physicians practicing in resource-variable settings must maintain a high index of suspicion. Any patient presenting with unexplained proptosis, bony pain, or elevated erythrocyte sedimentation rates requires systemic screening. Early electrophoretic screening and timely marrow evaluation prevent dangerous diagnostic delays. Ultimately, heightened vigilance across medical disciplines offers the only viable opportunity to diagnose plasma cell malignancies before irreversible tissue injury occurs.

What makes bilateral proptosis multiple myeloma an atypical clinical presentation?

Orbital plasmacytoma usually appears unilaterally and develops years after an initial multiple myeloma diagnosis. Presenting with bilateral proptosis as the first sign of an undiagnosed myeloma is exceedingly rare. This atypical manifestation reflects a high systemic tumor burden, aggressive plasma cell clone dissemination, and an ability of malignant cells to escape bone marrow regulation early in the disease course.

Which diagnostic tests confirm multiple myeloma in a patient presenting with orbital masses?

A definitive diagnosis requires tissue biopsy of the orbital or conjunctival lesion with immunohistochemical staining confirming monoclonal plasma cell infiltration. Clinicians must concurrently perform serum and urine protein electrophoresis with immunofixation to identify monoclonal paraproteins. Additionally, a bone marrow biopsy, complete skeletal survey, and serum free light chain assay confirm systemic bone marrow involvement and end-organ damage.

Why does extramedullary orbital involvement correlate with a poorer clinical prognosis?

Extramedullary disease signifies an advanced, dedifferentiated phenotype where plasma cells proliferate independently of bone marrow stromal signals. These aggressive clones frequently display adverse cytogenetic mutations, IgA isotype expression, and marked chemotherapy resistance. Consequently, despite rapid temporary responses to initial steroids or radiotherapy, patients face high relapse rates and substantially shortened overall survival.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Chadli S et al. Bilateral proptosis as the initial manifestation of multiple myeloma with orbital involvement: case report and literature review. Oxf Med Case Reports. 2026 Sep undefined. doi: 10.1093/omcr/omag176. PMID: 42798344.

Burkat CN, Van Buren JJ, Lucarelli MJ. Characteristics of orbital multiple myeloma: a case report and literature review. Surv Ophthalmol. 2009;54(6):697-704. doi: 10.1016/j.survophthal.2009.04.004. PMID: 19853874.

Malik A, Narang S, Handa U, Sood S. Multiple myeloma presenting as bilateral orbital proptosis. Indian J Ophthalmol. 2009;57(5):393-395. doi: 10.4103/0301-4738.55082. PMID: 19700883.